PubRank

D Gershenson

Author PubWeight™ 17.37‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer. Clin Cancer Res 2001 1.51
2 NCCN Prostate Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park) 1996 1.46
3 Reflectance spectroscopy for in vivo characterization of ovarian tissue. Lasers Surg Med 2001 1.24
4 Primary ovarian non-Hodgkin's lymphoma: outcome after treatment with combination chemotherapy. Gynecol Oncol 1997 1.23
5 Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 2000 1.01
6 Amplification and rearrangement of c-erb B proto-oncogenes in cancer of human female genital tract. Oncogene 1989 0.97
7 Fluorescence spectroscopy for in vivo characterization of ovarian tissue. Lasers Surg Med 2001 0.96
8 The induction of benign epithelial neoplasms of the ovaries of guinea pigs by testosterone stimulation: a potential animal model. Mod Pathol 1997 0.91
9 NCCN Ovarian Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park) 1996 0.88
10 Vessels within vessels in the myometrium. Am J Surg Pathol 2002 0.83
11 Loss of heterozygosity in human ovarian cancer on chromosome 19q. Gynecol Oncol 1997 0.82
12 Induction of epithelial neoplasms in the ovaries of guinea pigs by estrogenic stimulation. Gynecol Oncol 1998 0.82
13 Ovarian involvement by serous surface papillary carcinoma. Int J Gynecol Pathol 1994 0.81
14 Serous tumors involving extra-abdominal/extra-pelvic sites after the diagnosis of an ovarian serous neoplasm of low malignant potential. Am J Surg Pathol 2001 0.80
15 Unusual features of serous neoplasms of low malignant potential during pregnancy. Gynecol Oncol 1997 0.78
16 Biomarker modulation in a nonhuman rhesus primate model for ovarian cancer chemoprevention. Cancer Epidemiol Biomarkers Prev 2001 0.78
17 NCCN Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park) 1996 0.76
18 Should therapy of ovarian cancer patients be individualized based on underlying genetic defects? Clin Cancer Res 1999 0.75
19 Fetal biparietal diameter as a predictor of a mature lecithin/sphingomyelin ratio. Obstet Gynecol 1976 0.75
20 Palliative radiotherapy for ovarian cancer. Int J Radiat Oncol Biol Phys 1987 0.75
21 Activity of 2-fluoro-Ara AMP against gynecologic tumors in the soft agar assay. Invest New Drugs 1986 0.75
22 Utility of lymphangiography in the prediction of lymph node metastases in patients with cervical cancer. Int J Gynecol Cancer 2002 0.75
23 Combination chemotherapy for metastatic or recurrent adenocarcinoma of the cervix. J Clin Oncol 1987 0.75
24 High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Bone Marrow Transplant 2000 0.75
25 Intensive-dose ifosfamide and etoposide with filgrastim for cytoreduction before peripheral blood stem cell collection in patients with advanced ovarian cancer. Eur J Gynaecol Oncol 2000 0.75
26 Continuous-infusion vinblastine for treatment of refractory adenocarcinoma of the cervix. Cancer Treat Rep 1987 0.75